Abstract
Mesenchymal stem or progenitor cells remain the cells of choice for many regenerative treatment strategies in orthopedics. Due to a number of reasons such as regulatory burdens, time- and cost-efficiency and patient safety, bone-marrow-aspirate-concentrate (BMAC) has become an increasingly important source for application of mesenchymal stem cells (MSCs). However, specific surgical application techniques, as well as treatment regimes, often remain poorly discussed in the literature. This article aims to bridge this gap by providing comprehensive information for practicing surgeons to ease patient selection and clinical application of BMAC for chondral defects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have